Finoriq research workspace
BECTON DICKINSON & CO (BDX) Institutional Holdings & 13F Ownership
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices. Review BDX institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
- Company
- BECTON DICKINSON & CO (BDX)
- Ticker
- BDX
- Market Cap
- $42.8B
- Latest Price
- $155.38
- Industry
- Medical Devices
BECTON DICKINSON & CO (BDX) Top Institutional Holders
Top current 13F holders indexed for BECTON DICKINSON & CO (BDX). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | First Eagle Investment ManagementCIK 0001325447 | $1.9B | 3.2% | Filing2026-05-14 |
| 2 | Bill Nygren (advisor level)CIK 0000813917 | $349.4M | 0.47% | Filing2026-05-15 |
| 3 | First Pacific AdvisorsCIK 0001377581 | $311.4M | 4.4% | Filing2026-05-14 |
| 4 | Brandes Investment PartnersCIK 0001015079 | $238.3M | 1.7% | Filing2026-05-15 |
| 5 | Jeffrey SmithCIK 0001517137 | $100.1M | 2.2% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.